German China India

Germany: Management Structure

Bayer Appoints Stefan Oelrich to Join Board of Management and Lead Pharmaceuticals Division

| Editor: Ahlam Rais

Oelrich is currently a member of the Executive Committee of Sanofi with responsibility for the global diabetes and cardiovascular business.
Gallery: 1 image
Oelrich is currently a member of the Executive Committee of Sanofi with responsibility for the global diabetes and cardiovascular business. (Source: Bayer)

Stefan Oelrich will succeed Dieter Weinand as head of the Pharmaceuticals Division w.e.f. November 1, 2018. The Supervisory Board has also extended the contracts of Board of Management members Liam Condon, Head of Crop Science Division and Dr. Hartmut Klusik, Labor Director.

Leverkusen/Germany – The Supervisory Board of Bayer has appointed Stefan Oelrich (50) to the company’s Board of Management. He will succeed Dieter Weinand as head of the Pharmaceuticals Division as of November 1, 2018. Weinand is leaving the company for family reasons. He will be joining the Executive Committee of Sanofi and will be based in the United States. Oelrich is currently a member of the Executive Committee of Sanofi with responsibility for the global diabetes and cardiovascular business. He previously had a long career in Bayer’s Pharmaceuticals business.

In addition, the Supervisory Board extended the contract of Liam Condon (50) by five years, meaning that the Head of the Crop Science Division will continue to serve on the Board of Management until the end of 2023. The contract of Dr. Hartmut Klusik (62), Labor Director and Member of the Board of Management responsible for Human Resources, Technology and Sustainability, has been extended by a year until the end of 2019.

Stefan Oelrich was born in Wilhelmshaven, Germany, on June 1, 1968. After graduating from high school in Paris, France, he joined Bayer as a commercial trainee in 1989 and qualified as a commercial assistant in 1991. Over the next 20 years, he held a number of positions of increasing responsibility in the health care business in Latin America, Europe and the United States.

In 1998, after working in Argentina and Uruguay, Oelrich transferred to headquarters in Leverkusen for two years before assuming responsibility for Pharmaceuticals in Belgium. Between 2003 and 2005, he was Vice President of Marketing at Pharmaceuticals in the United States. He was subsequently appointed President of Healthcare and Diagnostics in France. In 2006, Oelrich returned to the United States as Senior Vice President and General Manager of Women’s Healthcare.

Five years later, he joined Sanofi as General Manager in Germany, Switzerland and Austria. In 2015, having been heavily involved in establishing Sanofi’s global Diabetes and Cardiovascular business unit, Oelrich became head of this business in Europe. At the same time, he served as Sanofi Europe Coordinator. In 2016, Oelrich became head of Sanofi’s global diabetes franchise. A year later, he was appointed Executive Vice President Diabetes & Cardiovascular on the Executive Committee of Sanofi.

Comments are being loaded ....

Leave a comment
  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Infos can be found under www.mycontentfactory.de (ID: 45495722 / Pharma & Food)